SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

OBI Phase 3 LANTERN trial shows 40.5% reduction in 30-day surgical site infections

Ondine Biomedical’s Phase 3 LANTERN trial reported a 40.5% reduction in 30-day surgical site infections using nasal photodisinfection. The company said the results had strong statistical support, with no significant adverse events; regulatory discussions and further analyses are ongoing.

OBI

Phase 3 LANTERN trial demonstrated a 40.5% reduction in 30-day surgical site infections using nasal photodisinfection, with strong statistical support and no significant adverse events. Regulatory discussions and further analyses are ongoing.Original document: Ondine Biomedical, Inc. [OBI] Press re…

Related stories